Abstract
Treatment strategies and treatment options have changed considerably over the past decade for Inflammatory Bowel Disease (IBD). Alongside this shift in therapeutic options has come an opportunity to personalize treatment decisions based on individual patient profiles and preferences. One of the most important aspects of therapy in IBD is treatment related risk, and an opportunity exists to personalize therapy through optimization of drug safety profiles in individual patients. In this review we discuss the potential risks of therapy in IBD, opportunities to mitigate those risks, and a personalized approach to consider when using these agents in clinical practice.
Keywords: Crohn's disease, ulcerative colitis, risk, adverse events, inflammatory bowel disease, infections
Graphical Abstract
Current Drug Targets
Title:Optimization of Drug Safety Profile in Inflammatory Bowel Disease Through a Personalized Approach
Volume: 19 Issue: 7
Author(s): Parambir S. Dulai and Corey A. Siegel*
Affiliation:
- Dartmouth-Hitchcock Medical Center, Lebanon, NH,United States
Keywords: Crohn's disease, ulcerative colitis, risk, adverse events, inflammatory bowel disease, infections
Abstract: Treatment strategies and treatment options have changed considerably over the past decade for Inflammatory Bowel Disease (IBD). Alongside this shift in therapeutic options has come an opportunity to personalize treatment decisions based on individual patient profiles and preferences. One of the most important aspects of therapy in IBD is treatment related risk, and an opportunity exists to personalize therapy through optimization of drug safety profiles in individual patients. In this review we discuss the potential risks of therapy in IBD, opportunities to mitigate those risks, and a personalized approach to consider when using these agents in clinical practice.
Export Options
About this article
Cite this article as:
Dulai S. Parambir and Siegel A. Corey *, Optimization of Drug Safety Profile in Inflammatory Bowel Disease Through a Personalized Approach, Current Drug Targets 2018; 19 (7) . https://dx.doi.org/10.2174/1389450118666170525114939
DOI https://dx.doi.org/10.2174/1389450118666170525114939 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Drug-Induced Thromboembolic Events in Patients with Malignancy
Cardiovascular & Hematological Disorders-Drug Targets Ceftriaxone-Vancomycin Drug Toxicity Reduction by VRP 1020 in Mus musculus Mice
Current Clinical Pharmacology Pneumonia Caused by Staphylococcus aureus
Current Respiratory Medicine Reviews The Need for Diagnostic Criteria in Systemic Vasculitis
Current Immunology Reviews (Discontinued) N-Containing Ag(I) and Hg(II) Complexes: A New Class of Antibiotics
Current Topics in Medicinal Chemistry Pre-clinical Impact of the Synergistic Mechanism of Daptomycin and Ceftaroline on Patients with Methicillin-resistant Staphylococcus aureus Bacteremia Infections
Current Reviews in Clinical and Experimental Pharmacology Bacterial Adaptation and Infection
Inflammation & Allergy - Drug Targets (Discontinued) Use of Oritavancin (Novel New Lipoglycopeptide) in the Treatment of Prosthetic Joint Infections (PJI): A Possible Alternative Novel Approach to a Difficult Problem
Infectious Disorders - Drug Targets Drug Delivery Systems Based on Titania Nanotubes and Active Agents for Enhanced Osseointegration of Bone Implants
Current Medicinal Chemistry Potential Application of Antimicrobial Peptides in the Treatment of Bacterial Biofilm Infections
Current Pharmaceutical Design Using PK/PD to Optimize Antibiotic Dosing for Critically Ill Patients
Current Pharmaceutical Biotechnology Total Synthesis of ME1036 Starting from Readily Available Inexpensive Materials
Letters in Organic Chemistry Bacteriophages and Phage-Derived Proteins – Application Approaches
Current Medicinal Chemistry Antibacterial Combination of Oleoresin from Copaifera multijuga Hayne and Biogenic Silver Nanoparticles Towards Streptococcus agalactiae
Current Pharmaceutical Biotechnology High Sensitivity C-Reactive Protein (hsCRP): A New Biochemical Marker of Atherosclerotic Vascular Disease
Current Cardiology Reviews A Review of Macrolide Treatment of Atherosclerosis and Abdominal Aortic Aneurysms
Current Drug Targets - Infectious Disorders The Impetus of COVID -19 in Multiple Organ Affliction Apart from Respiratory Infection: Pathogenesis, Diagnostic Measures and Current Treatment Strategy
Infectious Disorders - Drug Targets Aspirin Resistance in Cardiovascular Disease: Pathogenesis, Diagnosis and Clinical Impact
Current Pharmaceutical Design Clinical Pharmacology and Lesion Penetrating Properties of Second- and Third-Line Antituberculous Agents Used in the Management of Multidrug-Resistant (MDR) and Extensively-Drug Resistant (XDR) Tuberculosis
Current Clinical Pharmacology The Rise of Carbapenem-Resistant Acinetobacter baumannii
Current Pharmaceutical Design